Literature DB >> 25395620

Cysteinyl leukotriene 1 receptors as novel mechanosensors mediating myogenic tone together with angiotensin II type 1 receptors-brief report.

Ursula Storch1, Stephanie Blodow1, Thomas Gudermann2, Michael Mederos Y Schnitzler2.   

Abstract

OBJECTIVE: Myogenic vasoconstriction is mediated by vascular smooth muscle cells of resistance arteries sensing mechanical stretch. Angiotensin II AT1 receptors and in particular AT1BRs in murine vascular smooth muscle cells have been characterized as mechanosensors that cannot fully account for myogenic vasoconstriction observed. Therefore, we aimed at uncovering novel vascular mechanosensors by expression profiling and functional characterization of candidate proteins. APPROACH AND
RESULTS: Analyzing myogenic tone of isolated murine mesenteric arteries of AT1A and AT1B receptor double gene-deficient (AT1A/1B (-/-)) mice ex vivo, we observed a decreased myogenic tone at high intraluminal pressures and an unexpected hyper-reactivity at low intraluminal pressures because of upregulation of cysteinyl leukotriene 1 receptors (CysLT1Rs). Pharmacological blockade of CysLT1Rs with pranlukast significantly reduced myogenic tone not only in AT1A/1B (-/-) but also in wild-type arteries. In wild-type arteries, additional blockade of angiotensin II AT1 receptors with candesartan resulted in an additive reduction of myogenic tone. Furthermore, calcium imaging experiments were performed with fura-2-loaded human embryonic kidney 293 cells overexpressing CysLT1Rs and with isolated mesenteric vascular smooth muscle cells. Hypo-osmotically induced membrane stretch provoked calcium transients that were significantly reduced by pranlukast. Incubations of isolated mesenteric vascular smooth muscle cells with the 5-lipoxygenase inhibitor zileuton had no effect. Furthermore, the Gq/11-protein inhibitor YM 254890 profoundly reduced myogenic tone to the same extent as induced by the application of pranlukast plus candesartan.
CONCLUSIONS: Here, we identify a novel, hitherto unappreciated role of CysLT1Rs in vascular regulation. We identified CysLT1Rs as novel mechanosensors in the vasculature involved in myogenic vasoconstriction. Moreover, our findings suggest that myogenic tone is determined by AT1 and CysLT1 receptors acting together as mechanosensors via Gq/11-protein activation.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  G-protein–coupled receptors

Mesh:

Substances:

Year:  2014        PMID: 25395620     DOI: 10.1161/ATVBAHA.114.304844

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

Review 1.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 2.  Arteriolar oxygen reactivity: where is the sensor and what is the mechanism of action?

Authors:  William F Jackson
Journal:  J Physiol       Date:  2016-07-21       Impact factor: 5.182

3.  TRPV4 (Transient Receptor Potential Vanilloid 4) Channel-Dependent Negative Feedback Mechanism Regulates Gq Protein-Coupled Receptor-Induced Vasoconstriction.

Authors:  Kwangseok Hong; Eric L Cope; Leon J DeLalio; Corina Marziano; Brant E Isakson; Swapnil K Sonkusare
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

4.  Mechanical activation of angiotensin II type 1 receptors causes actin remodelling and myogenic responsiveness in skeletal muscle arterioles.

Authors:  Kwangseok Hong; Guiling Zhao; Zhongkui Hong; Zhe Sun; Yan Yang; Philip S Clifford; Michael J Davis; Gerald A Meininger; Michael A Hill
Journal:  J Physiol       Date:  2016-10-13       Impact factor: 5.182

5.  Angiotensin II Type 1 Receptor Mechanoactivation Involves RGS5 (Regulator of G Protein Signaling 5) in Skeletal Muscle Arteries: Impaired Trafficking of RGS5 in Hypertension.

Authors:  Kwangseok Hong; Min Li; Zahra Nourian; Gerald A Meininger; Michael A Hill
Journal:  Hypertension       Date:  2017-10-23       Impact factor: 10.190

6.  Central Role of P2Y6 UDP Receptor in Arteriolar Myogenic Tone.

Authors:  Gilles Kauffenstein; Sophie Tamareille; Fabrice Prunier; Charlotte Roy; Audrey Ayer; Bertrand Toutain; Marie Billaud; Brant E Isakson; Linda Grimaud; Laurent Loufrani; Pascal Rousseau; Pierre Abraham; Vincent Procaccio; Hannah Monyer; Cor de Wit; Jean-Marie Boeynaems; Bernard Robaye; Brenda R Kwak; Daniel Henrion
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-02       Impact factor: 8.311

7.  Myogenic Vasoconstriction Requires Canonical Gq/11 Signaling of the Angiotensin II Type 1 Receptor.

Authors:  Yingqiu Cui; Mario Kassmann; Sophie Nickel; Chenglin Zhang; Natalia Alenina; Yoland Marie Anistan; Johanna Schleifenbaum; Michael Bader; Donald G Welsh; Yu Huang; Maik Gollasch
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

8.  Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.

Authors:  Pu Yang; Bradley M Schmit; Chunhua Fu; Kenneth DeSart; S Paul Oh; Scott A Berceli; Zhihua Jiang
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

9.  Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.

Authors:  Mikako Hisamichi; Atsuko Kamijo-Ikemori; Takeshi Sugaya; Daisuke Ichikawa; Takayuki Natsuki; Seiko Hoshino; Kenjiro Kimura; Yugo Shibagaki
Journal:  FASEB J       Date:  2016-09-23       Impact factor: 5.191

10.  Dietary canolol protects the heart against the deleterious effects induced by the association of rapeseed oil, vitamin E and coenzyme Q10 in the context of a high-fat diet.

Authors:  Thibault Leger; Isabelle Hininger-Favier; Frédéric Capel; Alain Geloen; Jean-Paul Rigaudière; Chrystèle Jouve; Elodie Pitois; Gaelle Pineau; Carole Vaysse; Jean-Michel Chardigny; Marie-Caroline Michalski; Corinne Malpuech-Brugère; Luc Demaison
Journal:  Nutr Metab (Lond)       Date:  2018-02-13       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.